The endocrine management of growth failure and short stature has changed dramatically since the introduction of biosynthetic growth hormone (GH). To date, however, there are no published studies concerning the behavioral outcomes of individuals who had been treated entirely within the new era of biosynthetic GH therapy. Insofar as improvements in the treatment regimen have resulted in better growth and adult height outcomes (1), there is good reason to speculate that the psychosocial adjustment of individuals treated entirely in this new era will also be superior to that of patients who were treated when supplies of GH were limited. This belief is so pervasive that it has contributed to the expanded prescribing of GH to non-GH-deficient patient groups with short stature (2,3). Until behavioral outcome studies of these newer cohorts are completed, there remains much to be learned from the experiences and quality of life (QOL) outcomes of patients, now young adults or older, who have completed treatment, regardless of treatment era.